Update on Immununosuppressive Therapies for Dogs and Cats

Veterinary Clinics of North America - Small Animal Practice

Volumn 43, Issue 5, 2013, Pages 1149-1170

  Viviano, Katrina R ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Azathioprine; Chlorambucil; Cyclosporine; Glucocorticoids; Human immunoglobulin; Leflunomide; Mycophenolate; Vincristine

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BUDESONIDE; CHLORAMBUCIL; CYCLOSPORIN; DEXAMETHASONE; FLUTICASONE; GLUCOCORTICOID; HYDROCORTISONE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; LEFLUNOMIDE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; PYRIDOSTIGMINE; TACROLIMUS; VINCRISTINE;

ADD ON THERAPY; ADJUVANT THERAPY; ANUS FISTULA; AREA UNDER THE CURVE; ATOPIC DERMATITIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE SKIN DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; CAT DISEASE; CROHN DISEASE; CYTOPENIA; DERMATITIS; DOG DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG USE; DRY EYE; ENTERITIS; HEMOLYTIC ANEMIA; HISTIOCYTOSIS; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KERATOCONJUNCTIVITIS SICCA; LOW DRUG DOSE; LYMPHOCYTE FUNCTION; MYASTHENIA GRAVIS; NONHUMAN; PEMPHIGUS FOLIACEUS; POLYARTHRITIS; POLYMYOSITIS; PURE RED CELL ANEMIA; REMISSION; RESPIRATORY TRACT INFLAMMATION; RETINA DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ANIMALIA; CANIS FAMILIARIS;

EID: 84880955093     PISSN: 01955616     EISSN: 18781306     Source Type: Journal    
DOI: 10.1016/j.cvsm.2013.04.009     Document Type: Review

References (165)

1. Kuchroo V.K., Ohashi P.S., Sartor R.B., et al. Dysregulation of immune homeostasis in autoimmune diseases. Nat Med 2012, 18(1):42-47.
2. Davidson A., Diamond B. Autoimmune diseases. NEngl J Med 2001, 345(5):340-350.
3. Gershwin L.J. Autoimmune diseases in small animals. Vet Clin North Am Small Anim Pract 2010, 40(3):439-457.
4. Ferguson D., Dirikolu L., Hoenig M. Glucocorticoids, mineralocorticoids, adrenolytic drugs. Veterinary pharmacology and therapeutics 2009, 771-802. Wiley-Blackwll, Ames (IO). 9th edition. J.E. Riviere, M.G. Papich (Eds.).
5. Zen M., Canova M., Campana C., et al. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011, 10(6):305-310.
6. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function*. Annu Rev Immunol 2000, 18:309-345.
7. Al-Ghazlat S. Immunosuppressive therapy for canine immune-mediated hemolytic anemia. Compend Contin Educ Vet 2009, 31(1):33-41.
8. Buttgereit F., Scheffold A. Rapid glucocorticoid effects on immune cells. Steroids 2002, 67(6):529-534.
9. Friedman D., Netti F., Schreiber A.D. Effect of estradiol and steroid analogues on the clearance of immunoglobulin G-coated erythrocytes. JClin Invest 1985, 75(1):162-167.
10. Gernsheimer T., Stratton J., Ballem P.J., et al. Mechanisms of response to treatment in autoimmune thrombocytopenic purpura. NEngl J Med 1989, 320(15):974-980.
11. Miller E. Immunosuppressive therapy in the treatment of immune-mediated disease. JVet Intern Med 1992, 6(4):206-213.
12. Galon J., Franchimont D., Hiroi N., et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002, 16(1):61-71.
13. Boston S.E., Moens N.M., Kruth S.A., et al. Endoscopic evaluation of the gastroduodenal mucosa to determine the safety of short-term concurrent administration of meloxicam and dexamethasone in healthy dogs. Am J Vet Res 2003, 64(11):1369-1375.
14. Plumb D.C. Plumb's veterinary drug Handbook 2011, Iowa State University Press, Ames (IA).
15. Graham-Mize C., Rosser E. Bioavailability and activity of prednisone and prednisolone in the feline patient. Vet Dermatol 2004, 15:7. [abstract].
16. Ballard P.L., Carter J.P., Graham B.S., et al. Aradioreceptor assay for evaluation of the plasma glucocorticoid activity of natural and synthetic steroids in man. JClin Endocrinol Metab 1975, 41(2):290-304.
17. Cantrill H.L., Waltman S.R., Palmberg P.F., et al. Invitro determination of relative corticosteroid potency. JClin Endocrinol Metab 1975, 40(6):1073-1077.
18. Stroup S.T., Behrend E.N., Kemppainen R.J., et al. Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. Am J Vet Res 2006, 67(7):1173-1178.
19. Tumulty J.W., Broussard J.D., Steiner J.M., et al. Clinical effects of short-term oral budesonide on the hypothalamic-pituitary-adrenal axis in dogs with inflammatory bowel disease. JAm Anim Hosp Assoc 2004, 40(2):120-123.
20. De Cassan C., Fiorino G., Danese S. Second-generation corticosteroids for the treatment of Crohn's disease and ulcerative colitis: more effective and less side effects?. Dig Dis 2012, 30(4):368-375.
21. Pietra M., Fracassi F., Diana A., et al. Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease. Am J Vet Res 2013, 74(1):78-83.
22. Bexfield N.H., Foale R.D., Davison L.J., et al. Management of 13 cases of canine respiratory disease using inhaled corticosteroids. JSmall Anim Pract 2006, 47(7):377-382.
23. Cohn L.A., DeClue A.E., Cohen R.L., et al. Effects of fluticasone propionate dosage in an experimental model of feline asthma. JFeline Med Surg 2010, 12(2):91-96.
24. Leemans J., Kirschvink N., Clercx C., et al. Effect of short-term oral and inhaled corticosteroids on airway inflammation and responsiveness in a feline acute asthma model. Vet J 2012, 192(1):41-48.
25. Stahelin H. Cyclosporin A. Historical background. Prog Allergy 1986, 38:19-27.
26. Halloran P.F. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996, 10:118-123.
27. Whitley N.T., Day M.J. Immunomodulatory drugs and their application to the management of canine immune-mediated disease. JSmall Anim Pract 2011, 52(2):70-85.
28. Aronson L.R., Stumhofer J.S., Drobatz K.J., et al. Effect of cyclosporine, dexamethasone, and human CTLA4-Ig on production of cytokines in lymphocytes of clinically normal cats and cats undergoing renal transplantation. Am J Vet Res 2011, 72(4):541-549.
29. Archer T.M., Fellman C.L., Stokes J.V., et al. Pharmacodynamic monitoring of canine T-cell cytokine responses to oral cyclosporine. JVet Intern Med 2011, 25(6):1391-1397.
30. Fellman C.L., Stokes J.V., Archer T.M., et al. Cyclosporine A affects the invitro expression of T cell activation-related molecules and cytokines in dogs. Vet Immunol Immunopathol 2011, 140(3-4):175-180.
31. Robson D. Review of the pharmacokinetics, interactions and adverse reactions of cyclosporine in people, dogs and cats. Vet Rec 2003, 152(24):739-748.
32. Schmiedt C.W., Grimes J.A., Holzman G., et al. Incidence and risk factors for development of malignant neoplasia after feline renal transplantation and cyclosporine-based immunosuppression. Vet Comp Oncol 2009, 7(1):45-53.
33. Viviano K.R., Webb J.L. Clinical use of cyclosporine as an adjunctive therapy in the management of feline idiopathic pure red cell aplasia. JFeline Med Surg 2011, 13(12):885-895.
34. Thomason J., Lunsford K., Stokes J., et al. The effects of cyclosporine on platelet function and cyclooxygenase expression in normal dogs. JVet Intern Med 2012, 26(6):1389-1401.
35. Averna M., Barbagallo C.M., Ganci A., et al. Determinants of enhanced thromboxane biosynthesis in renal transplantation. Kidney Int 2001, 59(4):1574-1579.
36. Jespersen B., Thiesson H.C., Henriksen C., et al. Differential effects of immunosuppressive drugs on COX-2 activity invitro and in kidney transplant patients invivo. Nephrol Dial Transplant 2009, 24(5):1644-1655.
37. Sahin G., Akay O.M., Kus E., et al. Effects of immunosuppressive drugs on platelet aggregation and soluble P-selectin levels in renal transplant patients. Ren Fail 2009, 31(2):111-117.
38. Katayama M., Igarashi H., Fukai K., et al. Fluconazole decreases cyclosporine dosage in renal transplanted dogs. Res Vet Sci 2010, 89(1):124-125.
39. Katayama M., Katayama R., Kamishina H. Effects of multiple oral dosing of itraconazole on the pharmacokinetics of cyclosporine in cats. JFeline Med Surg 2010, 12(6):512-514.
40. McAnulty J.F., Lensmeyer G.L. The effects of ketoconazole on the pharmacokinetics of cyclosporine A in cats. Vet Surg 1999, 28(6):448-455.
41. Patricelli A.J., Hardie R.J., McAnulty J.E. Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs. JAm Vet Med Assoc 2002, 220(7):1009-1016.
42. Katayama M., Nishijima N., Okamura Y., et al. Interaction of clarithromycin with cyclosporine in cats: pharmacokinetic study and case report. JFeline Med Surg 2012, 14(4):257-261.
43. Amatori F.M., Meucci V., Giusiani M., et al. Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs. Vet Rec 2004, 154(6):180-181.
44. Radwanski N.E., Cerundolo R., Shofer F.S., et al. Effects of powdered whole grapefruit and metoclopramide on the pharmacokinetics of cyclosporine in dogs. Am J Vet Res 2011, 72(5):687-693.
45. Trepanier L.A. Cytochrome P450 and its role in veterinary drug interactions. Vet Clin North Am Small Anim Pract 2006, 36(5):975-985. v.
46. Calne R.Y., White D.J., Thiru S., et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978, 2(8104-5):1323-1327.
47. Griffiths L.G., Sullivan M., Borland W.W. Cyclosporin as the sole treatment for anal furunculosis: preliminary results. JSmall Anim Pract 1999, 40(12):569-572.
48. Hardie R.J., Gregory S.P., Tomlin J., et al. Cyclosporine treatment of anal furunculosis in 26 dogs. JSmall Anim Pract 2005, 46(1):3-9.
49. Mathews K.A., Sukhiani H.R. Randomized controlled trial of cyclosporine for treatment of perianal fistulas in dogs. JAm Vet Med Assoc 1997, 211(10):1249-1253.
50. O'Neill T., Edwards G.A., Holloway S. Efficacy of combined cyclosporine A and ketoconazole treatment of anal furunculosis. JSmall Anim Pract 2004, 45(5):238-243.
51. Moore C.P. Immunomodulating agents. Vet Clin North Am Small Anim Pract 2004, 34(3):725-737.
52. Guaguere E., Steffan J., Olivry T. Cyclosporin A: a new drug in the field of canine dermatology. Vet Dermatol 2004, 15(2):61-74.
53. Olivry T., Foster A.P., Mueller R.S., et al. Interventions for atopic dermatitis in dogs: a systematic review of randomized controlled trials. Vet Dermatol 2010, 21(1):4-22.
54. Steffan J., Favrot C., Mueller R. Asystemic review and meta-analysis of the efficacy and safety of cyclosporin for the treatment of atopic dermatitis in dogs. Vet Dermatol 2006, 17:3-16.
55. Allenspach K., Rufenacht S., Sauter S., et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid-refractory inflammatory bowel disease. JVet Intern Med 2006, 20(2):239-244.
56. Grundy S.A., Barton C. Influence of drug treatment on survival of dogs with immune-mediated hemolytic anemia: 88 cases (1989-1999). JAm Vet Med Assoc 2001, 218(4):543-546.
57. Nakamura R.K., Tompkins E., Bianco D. Therapeutic options for immune-mediated thrombocytopenia. JVet Emerg Crit Care (San Antonio) 2012, 22(1):59-72.
58. Whalen R.D., Tata P.N., Burckart G.J., et al. Species differences in the hepatic and intestinal metabolism of cyclosporine. Xenobiotica 1999, 29(1):3-9.
59. Trifilio S.M., Scheetz M., Borensztajn J., et al. Variability of cyclosporine concentrations by HPLC and TDX monoclonal assay methods, application of a correction factor, and description of a novel clinical approach to determine the practical consequences of changing assay technique. Clin Transplant 2013, 27(1):154-161.
60. Teramura M., Kimura A., Iwase S., et al. Treatment of severe aplastic anemia with antithymocyte globulin and cyclosporin A with or without G-CSF in adults: a multicenter randomized study in Japan. Blood 2007, 110(6):1756-1761.
61. Nam H.S., McAnulty J.F., Kwak H.H., et al. Gingival overgrowth in dogs associated with clinically relevant cyclosporine blood levels: observations in a canine renal transplantation model. Vet Surg 2008, 37(3):247-253.
62. Mehl M.L., Kyles A.E., Craigmill A.L., et al. Disposition of cyclosporine after intravenous and multi-dose oral administration in cats. JVet Pharmacol Ther 2003, 26(5):349-354.
63. Nashan B., Cole E., Levy G., et al. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation 2002, 73(Suppl 9):S3-S11.
64. Nafe LA, Dodam JR, Reinero CR. ExVivo immunosuppression of canine T lymphocyte-specific proliferation using dexamethasone, cyclosporine, and active metabolites of azathioprine and leflunomide in a flow cytometric assay. Paper presented at: 2012 Proceedings ACVIM. New Orleans, LA. ACVIM Forum, May 30-June 2, 2012.
65. Stanley B.J., Hauptman J.G. Long-term prospective evaluation of topically applied 0.1% tacrolimus ointment for treatment of perianal sinuses in dogs. JAm Vet Med Assoc 2009, 235(4):397-404.
66. Hendrix D.V., Adkins E.A., Ward D.A., et al. An investigation comparing the efficacy of topical ocular application of tacrolimus and cyclosporine in dogs. Vet Med Int 2011, 2011:487592.
67. Chung T.H., Ryu M.H., Kim D.Y., et al. Topical tacrolimus (FK506) for the treatment of feline idiopathic facial dermatitis. Aust Vet J 2009, 87(10):417-420.
68. Aarbakke J., Janka-Schaub G., Elion G.B. Thiopurine biology and pharmacology. Trends Pharmacol Sci 1997, 18(1):3-7.
69. Elion G.B. The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine. Ann N Y Acad Sci 1993, 685:400-407.
70. Houston D.M., Taylor J.A. Acute pancreatitis and bone marrow suppression in a dog given azathioprine. Can Vet J 1991, 32(8):496-497.
71. Schwab M., Schaffeler E., Marx C., et al. Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. Pharmacogenetics 2002, 12(6):429-436.
72. Piek C.J., Junius G., Dekker A., et al. Idiopathic immune-mediated hemolytic anemia: treatment outcome and prognostic factors in 149 dogs. JVet Intern Med 2008, 22(2):366-373.
73. Dubinsky M.C., Lamothe S., Yang H.Y., et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118(4):705-713.
74. El-Beshbishy H.A., Tork O.M., El-Bab M.F., et al. Antioxidant and antiapoptotic effects of green tea polyphenols against azathioprine-induced liver injury in rats. Pathophysiology 2011, 18(2):125-135.
75. Kruh J., Foster C.S. Corticosteroid-sparing agents: conventional systemic immunosuppressants. Dev Ophthalmol 2012, 51:29-46.
76. Harkin K.R., Phillips D., Wilkerson M. Evaluation of azathioprine on lesion severity and lymphocyte blastogenesis in dogs with perianal fistulas. JAm Anim Hosp Assoc 2007, 43(1):21-26.
77. Ogilvie G.K., Felsburg P.J., Harris C.W. Short-term effect of cyclophosphamide and azathioprine on selected aspects of the canine blastogenic response. Vet Immunol Immunopathol 1988, 18(2):119-127.
78. Reimer M.E., Troy G.C., Warnick L.D. Immune-mediated hemolytic anemia: 70 cases (1988-1996). JAm Anim Hosp Assoc 1999, 35(5):384-391.
79. Weinkle T.K., Center S.A., Randolph J.F., et al. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). JAm Vet Med Assoc 2005, 226(11):1869-1880.
80. Kidd L.B., Salavaggione O.E., Szumlanski C.L., et al. Thiopurine methyltransferase activity in red blood cells of dogs. JVet Intern Med 2004, 18(2):214-218.
81. Beale K.M., Altman D., Clemmons R.R., et al. Systemic toxicosis associated with azathioprine administration in domestic cats. Am J Vet Res 1992, 53(7):1236-1240.
82. Salavaggione O.E., Yang C., Kidd L.B., et al. Cat red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics. JPharmacol Exp Ther 2004, 308(2):617-626.
83. Berns A., Rubenfeld S., Rymzo W.T., et al. Hazard of combining allopurinol and thiopurine. NEngl J Med 1972, 286(13):730-731.
84. Ansari A., Elliott T., Baburajan B., et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008, 28(6):734-741.
85. Govani S.M., Higgins P.D. Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD. JCrohns Colitis 2010, 4(4):444-449.
86. Sparrow M.P., Hande S.A., Friedman S., et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22(5):441-446.
87. Benitah N., de Lorimier L.P., Gaspar M., et al. Chlorambucil-induced myoclonus in a cat with lymphoma. JAm Anim Hosp Assoc 2003, 39(3):283-287.
88. Barrs V.R., Beatty J.A. Feline alimentary lymphoma: 2. Further diagnostics, therapy and prognosis. JFeline Med Surg 2012, 14(3):191-201.
89. Kiselow M.A., Rassnick K.M., McDonough S.P., et al. Outcome of cats with low-grade lymphocytic lymphoma: 41 cases (1995-2005). JAm Vet Med Assoc 2008, 232(3):405-410.
90. Lingard A.E., Briscoe K., Beatty J.A., et al. Low-grade alimentary lymphoma: clinicopathological findings and response to treatment in 17 cases. JFeline Med Surg 2009, 11(8):692-700.
91. Jergens A.E. Feline idiopathic inflammatory bowel disease: what we know and what remains to be unraveled. JFeline Med Surg 2012, 14(7):445-458.
92. Trepanier L. Idiopathic inflammatory bowel disease in cats. Rational treatment selection. JFeline Med Surg 2009, 11(1):32-38.
93. Willard M.D. Feline inflammatory bowel disease: a review. JFeline Med Surg 1999, 1(3):155-164.
94. Wondratschek C., Weingart C., Kohn B. Primary immune-mediated thrombocytopenia in cats. JAm Anim Hosp Assoc 2010, 46(1):12-19.
95. Bianco D., Hardy R.M. Treatment of Evans' syndrome with human intravenous immunoglobulin and leflunomide in a diabetic dog. JAm Anim Hosp Assoc 2009, 45(3):147-150.
96. Rozanski E.A., Callan M.B., Hughes D., et al. Comparison of platelet count recovery with use of vincristine and prednisone or prednisone alone for treatment for severe immune-mediated thrombocytopenia in dogs. JAm Vet Med Assoc 2002, 220(4):477-481.
97. Boruchov D.M., Gururangan S., Driscoll M.C., et al. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood 2007, 110(10):3526-3531.
98. Golden D.L., Langston V.C. The use of vincristine and vinblastine in dogs and cats. JAm Vet Med Assoc 1988, 93:1114-1117.
99. Wohl J.S., Cotter S.M. Approach to complications of anticancer therapy in emergency practice. JVet Emerg Crit Care 1995, 5:61-76.
100. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs 2011, 27(1):82-90.
101. Villalobos A. Dealing with chemotherapy extravasations: a new technique. JAm Anim Hosp Assoc 2006, 42(4):321-325.
102. Chamouni P., Lenain P., Buchonnet G., et al. Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine. Transfus Sci 2000, 23(2):101-106.
103. Ferrara F., Copia C., Annunziata M., et al. Vincristine as salvage treatment for refractory thrombotic thrombocytopenic purpura. Ann Hematol 1999, 78(11):521-523.
104. Lewis D., Meyers K.M. Canine idiopathic thrombocytopenia purpura. JVet Intern Med 1996, 10:207-218.
105. Mackin A.J., Allen D.G., Johnston I.B. Effects of vincristine and prednisone on platelet numbers and function in clinically normal dogs. Am J Vet Res 1995, 56(1):100-108.
106. Grau-Bassas E.R., Kociba G.J., Couto C.G. Vincristine impairs platelet aggregation in dogs with lymphoma. JVet Intern Med 2000, 14(1):81-85.
107. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. NEngl J Med 2001, 345(10):747-755.
108. Emmi L., Chiarini F. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002, 23(Suppl 1):S1-S8.
109. Knezevic-Maramica I., Kruskall M.S. Intravenous immune globulins: an update for clinicians. Transfusion 2003, 43(10):1460-1480.
110. Vaccaro C., Zhou J., Ober R.J., et al. Engineering the Fc region of immunoglobulin G to modulate invivo antibody levels. Nat Biotechnol 2005, 23(10):1283-1288.
111. Kroez M., Kanzy E.J., Gronski P., et al. Hypotension with intravenous immunoglobulin therapy: importance of pH and dimer formation. Biologicals 2003, 31(4):277-286.
112. Marie I., Maurey G., Herve F., et al. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006, 155(4):714-721.
113. Cayco A.V., Perazella M.A., Hayslett J.P. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. JAm Soc Nephrol 1997, 8(11):1788-1794.
114. Sekul E.A., Cupler E.J., Dalakas M.C. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994, 121(4):259-262.
115. Orbach H., Katz U., Sherer Y., et al. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005, 29(3):173-184.
116. Byrne K.P., Giger U. Use of human immunoglobulin for treatment of severe erythema multiforme in a cat. JAm Vet Med Assoc 2002, 220(2):197-201. 183-94.
117. Grozdanic S., Harper M., Kecova H. Antibody-mediated retinopathies in canine patients: mechanism, diagnosis, and treatment modalities. Vet Clin North Am Small Anim Pract 2008, 38(2):361-387.
118. Rahilly L.J., Keating J.H., O'Toole T.E. The use of intravenous human immunoglobulin in treatment of severe pemphigus foliaceus in a dog. JVet Intern Med 2006, 20(6):1483-1486.
119. Scott-Moncrieff J.C., Reagan W.J., Snyder P.W., et al. Intravenous administration of human immune globulin in dogs with immune-mediated hemolytic anemia. JAm Vet Med Assoc 1997, 210(11):1623-1627.
120. Trotman T.K., Phillips H., Fordyce H., et al. Treatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs. JAm Anim Hosp Assoc 2006, 42(4):312-320.
121. Bianco D., Armstrong P.J., Washabau R.J. Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. JVet Intern Med 2007, 21(4):694-699.
122. Bianco D., Armstrong P.J., Washabau R.J. Aprospective, randomized, double-blinded, placebo-controlled study of human intravenous immunoglobulin for the acute management of presumptive primary immune-mediated thrombocytopenia in dogs. JVet Intern Med 2009, 23(5):1071-1078.
123. Tsuchiya R., Akutsu Y., Ikegami A., et al. Prothrombotic and inflammatory effects of intravenous administration of human immunoglobulin G in dogs. JVet Intern Med 2009, 23(6):1164-1169.
124. Whelan M.F., O'Toole T.E., Chan D.L., et al. Use of human immunoglobulin in addition to glucocorticoids for the initial treatment of dogs with immune-mediated hemolytic anemia. JVet Emerg Crit Care (San Antonio) 2009, 19(2):158-164.
125. Nuttall T.J., Malham T. Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. JSmall Anim Pract 2004, 45(7):357-361.
126. Ahmed A.R., Dahl M.V. Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003, 139(8):1051-1059.
127. Chen C., Danekas L.H., Ratko T.A., et al. Amulticenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000, 34(3):295-299.
128. Darabi K., Abdel-Wahab O., Dzik W.H. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 2006, 46(5):741-753.
129. Durandy A. Immunoglobulin class switch recombination: study through human natural mutants. Philos Trans R Soc Lond B Biol Sci 2009, 364(1517):577-582.
130. Foster C.S., Chang P.Y., Ahmed A.R. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010, 117(5):861-869.
131. Reagan W.J., Scott-Moncrieff C., Christian J., et al. Effects of human intravenous immunoglobulin on canine monocytes and lymphocytes. Am J Vet Res 1998, 59(12):1568-1574.
132. Scott-Moncrieff J.C., Reagan W.J. Human intravenous immunoglobulin therapy. Semin Vet Med Surg (Small Anim) 1997, 12(3):178-185.
133. Kellerman D.L., Bruyette D.S. Intravenous human immunoglobulin for the treatment of immune-mediated hemolytic anemia in 13 dogs. JVet Intern Med 1997, 11(6):327-332.
134. Spurlock N.K., Prittie J.E. Areview of current indications, adverse effects, and administration recommendations for intravenous immunoglobulin. JVet Emerg Crit Care (San Antonio) 2011, 21(5):471-483.
135. Czaja A.J. Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation. Dig Dis Sci 2012, 57(9):2248-2266.
136. Danovitch G.M. Mycophenolate mofetil: a decade of clinical experience. Transplantation 2005, 80(Suppl 2):S272-S274.
137. Ritter M.L., Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 2009, 11(4):290-297.
138. Drosos A.A. Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy. Drugs 2002, 62(6):891-907.
139. Juel V.C., Massey J.M. Myasthenia gravis. Orphanet J Rare Dis 2007, 2:44.
140. Orvis A.K., Wesson S.K., Breza T.S., et al. Mycophenolate mofetil in dermatology. JAm Acad Dermatol 2009, 60(2):183-199. [quiz: 200-2].
141. Mehling A., Grabbe S., Voskort M., et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. JImmunol 2000, 165(5):2374-2381.
142. Morath C., Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 2003, 41(10):465-469.
143. Behrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001, 24(9):645-663.
144. Chanda S.M., Sellin J.H., Torres C.M., et al. Comparative gastrointestinal effects of mycophenolate mofetil capsules and enteric-coated tablets of sodium-mycophenolic acid in beagle dogs. Transplant Proc 2002, 34(8):3387-3392.
145. Dewey C.W., Cerda-Gonzalez S., Fletcher D.J., et al. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008). JAm Vet Med Assoc 2010, 236(6):664-668.
146. Dewey C.W., Booth D.M. Pharmacokinetics of single-dose oral and intravenous mycophenolate mofetil adminstraton in normal dogs. JVet Intern Med 2001, 15:304. [abstract].
147. Naderer O.J., Dupuis R.E., Heinzen E.L., et al. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. JClin Pharmacol 2005, 45(2):219-226.
148. Gabardi S., Olyaei A. Evaluation of potential interactions between mycophenolic acid derivatives and proton pump inhibitors. Ann Pharmacother 2012, 46(7-8):1054-1064.
149. Manitpisitkul W., McCann E., Lee S., et al. Drug interactions in transplant patients: what everyone should know. Curr Opin Nephrol Hypertens 2009, 18(5):404-411.
150. Lam S., Partovi N., Ting L.S., et al. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?. Ann Pharmacother 2008, 42(7):1037-1047.
151. Yuki M., Sugimoto N., Otsuka H., et al. Recovery of a dog from aplastic anaemia after treatment with mycophenolate mofetil. Aust Vet J 2007, 85(12):495-497.
152. Ginel P.J., Blanco B., Lucena R., et al. Steroid-sparing effect of mycophenolate mofetil in the treatment of a subepidermal blistering autoimmune disease in a dog. JS Afr Vet Assoc 2010, 81(4):253-257.
153. Bacek L.M., Macintire D.K. Treatment of primary immune-mediated hemolytic anemia with mycophenolate mofetil in two cats. JVet Emerg Crit Care (San Antonio) 2011, 21(1):45-49.
154. Langman L.J., Shapiro A.M., Lakey J.R., et al. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. Transplantation 1996, 61(1):87-92.
155. Lupu M., McCune J.S., Kuhr C.S., et al. Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy. Biol Blood Marrow Transplant 2006, 12(12):1352-1354.
156. Marder W., McCune W.J. Advances in immunosuppressive therapy. Semin Respir Crit Care Med 2007, 28(4):398-417.
157. Pinto P., Dougados M. Leflunomide in clinical practice. Acta Reumatol Port 2006, 31(3):215-224.
158. Tallantyre E., Evangelou N., Constantinescu C.S. Spotlight on teriflunomide. Int MS J 2008, 15(2):62-68.
159. Gregory C.R., Silva H.T., Patz J.D., et al. Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats. Transplant Proc 1998, 30(4):1047-1048.
160. Kyles A.E., Gregory C.R., Craigmill A.L. Comparison of the invitro antiproliferative effects of five immunosuppressive drugs on lymphocytes in whole blood from cats. Am J Vet Res 2000, 61(8):906-909.
161. Colopy S.A., Baker T.A., Muir P. Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008). JAm Vet Med Assoc 2010, 236(3):312-318.
162. Gregory C.R., Stewart A., Sturges B., et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Transplant Proc 1998, 30(8):4143-4148.
163. McChesney L.P., Xiao F., Sankary H.N., et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994, 57(12):1717-1722.
164. Affolter V.K., Moore P.F. Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. Am J Dermatopathol 2000, 22:40-48.
165. Hanna F.Y. Disease modifying treatment for feline rheumatoid arthritis. Vet Comp Orthop Traumatol 2005, 18(2):94-99.